Erschienen:
Journal of Neurosurgery Publishing Group (JNSPG), 1994
Erschienen in:Journal of Neurosurgery
Sprache:
Nicht zu entscheiden
DOI:
10.3171/jns.1994.81.5.0741
ISSN:
0022-3085
Entstehung:
Anmerkungen:
Beschreibung:
<jats:p content-type="fine-print">✓ Because of the short range of the highly energetic particles helium-4 and lithium-7 that results from neutron-induced disintegration of boron-10, the efficacy of Boron Neutron Capture Therapy (BNCT) is heavily dependent on <jats:sup>10</jats:sup>B-microlocation. Despite the crucial importance of boron-10, there is little specific information with regard to the agent currently used for inducing BNCT, namely Na<jats:sub>2</jats:sub>B<jats:sub>12</jats:sub>H<jats:sub>11</jats:sub>SH. In the present study, a subcellular <jats:sup>10</jats:sup>B-location was investigated in tumor tissue obtained from seven patients with glioblastoma World Health Organization Grade IV. These patients received Na<jats:sub>2</jats:sub>B<jats:sub>12</jats:sub>H<jats:sub>11</jats:sub>SH at doses used in therapeutic trials (75 mg/kg body weight in five patients, and 150 mg/kg body weight in two patients, respectively). In three cases, boron-10 was identified in glioblastoma cells by laser microprobe mass analysis. In these tumors, boron-10 was found only in the nuclei of neoplastic cells but not in other cell compartments. These preliminary results suggest a predominant association of Na<jats:sub>2</jats:sub>B<jats:sub>12</jats:sub>H<jats:sub>11</jats:sub>SH with the nuclei of malignant glioma cells and thus support the value of Na<jats:sub>2</jats:sub>B<jats:sub>12</jats:sub>H<jats:sub>11</jats:sub>SH as a suitable boron carrier for BNCT.</jats:p>